Cancer immunotherapy with CAR-T cells - Behold the future

Charlotte Graham; Rebecca Hewitson; Antonio Pagliuca; Reuben Benjamin

doi:10.7861/clinmedicine.18-4-324

Cancer immunotherapy with CAR-T cells - Behold the future

Charlotte Graham^*, Rebecca Hewitson, Antonio Pagliuca, Reuben Benjamin

^*Corresponding author for this work

Institute of Psychiatry, Psychology & Neuroscience

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.¹ Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.

Original language	English
Pages (from-to)	324-328
Number of pages	5
Journal	Clinical Medicine, Journal of the Royal College of Physicians of London
Volume	18
Issue number	4
DOIs	https://doi.org/10.7861/clinmedicine.18-4-324
Publication status	Published - 1 Aug 2018

Keywords

Cancer immunotherapy
CAR-T cell-related encephalopathy syndrome
CAR-T cells
Cellular therapy
Cytokine release syndrome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7861/clinmedicine.18-4-324

Cite this

@article{c0cae337c6ed4d15b4c1bb4bcb1db8da,

title = "Cancer immunotherapy with CAR-T cells - Behold the future",

abstract = "Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.",

keywords = "Cancer immunotherapy, CAR-T cell-related encephalopathy syndrome, CAR-T cells, Cellular therapy, Cytokine release syndrome",

author = "Charlotte Graham and Rebecca Hewitson and Antonio Pagliuca and Reuben Benjamin",

year = "2018",

month = aug,

day = "1",

doi = "10.7861/clinmedicine.18-4-324",

language = "English",

volume = "18",

pages = "324--328",

journal = "Clinical Medicine, Journal of the Royal College of Physicians of London",

issn = "1470-2118",

publisher = "Royal College of Physicians",

number = "4",

}

TY - JOUR

T1 - Cancer immunotherapy with CAR-T cells - Behold the future

AU - Graham, Charlotte

AU - Hewitson, Rebecca

AU - Pagliuca, Antonio

AU - Benjamin, Reuben

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.

AB - Cellular therapy is a key tool to treat haematological malignancies. Over 40,000 allogeneic and autologous haematopoietic stem cell transplants (HSCTs) are performed annually across Europe.1 Since 2017, a new T cell therapy, chimeric antigen receptor-T (CAR-T) cells have been licensed outside clinical trials. CAR-T cells have extremely potent antitumour activity, but also have a profile of toxic side effects not seen before. Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. Patients frequently require admission to intensive care, and management from a number of medical specialties. This exciting and powerful new therapy requires the formation of new multispecialty medical teams for safe delivery and to successfully manage the resultant complications.

KW - Cancer immunotherapy

KW - CAR-T cell-related encephalopathy syndrome

KW - CAR-T cells

KW - Cellular therapy

KW - Cytokine release syndrome

UR - http://www.scopus.com/inward/record.url?scp=85051401334&partnerID=8YFLogxK

U2 - 10.7861/clinmedicine.18-4-324

DO - 10.7861/clinmedicine.18-4-324

M3 - Article

C2 - 30072559

AN - SCOPUS:85051401334

SN - 1470-2118

VL - 18

SP - 324

EP - 328

JO - Clinical Medicine, Journal of the Royal College of Physicians of London

JF - Clinical Medicine, Journal of the Royal College of Physicians of London

IS - 4

ER -

Cancer immunotherapy with CAR-T cells - Behold the future

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this